Physician profile
Anabel Lucanie
NPI 1295736577
$2,927.96
in general payments reported to CMS, 2019-2025
34 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $298 · 2021: $216 · 2022: $498 · 2023: $331 · 2024: $341 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $368.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $335.90 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.74 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $246.53 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $192.44 | 2019-2025 | |
| Abbvie INC. | $170.56 | 2020-2024 | |
| Astellas Pharma US INC | $168.35 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $154.87 | 2019-2025 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.49 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $121.75 | 2019-2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $86.73 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $80.69 | 2019-2021 | |
| Lilly USA, LLC | $62.25 | 2021-2024 | Mounjaro |
| Novo Nordisk INC | $51.11 | 2023-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $45.37 | 2024 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $40.86 | 2020-2025 | Watchman Access System |
| Medtronic, INC. | $38.76 | 2023 | Minimed 780g |
| Phathom Pharmaceuticals, INC. | $38.00 | 2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $31.67 | 2023 | Edarbi |
| Sunovion Pharmaceuticals INC. | $28.10 | 2022 | |
| Exact Sciences Corporation | $26.55 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $26.50 | 2019 | |
| Genentech USA, INC. | $25.92 | 2019-2020 | |
| Horizon Therapeutics Plc | $25.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.27 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.48 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.96 | 2019 | |
| Mannkind Corporation | $14.95 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.90 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2019 | |
| Ge Healthcare | $14.35 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $13.95 | 2025 | Neffy |
| Jazz Pharmaceuticals INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anabel Lucanie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.